Trial Profile
An observational study to evaluate the safety and efficacy of bosentan as a mono-therapy in patients with pulmonary arterial hypertension and congenital heart disease (Eisenmenger syndrome)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2015
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Eisenmenger complex; Pulmonary arterial hypertension
- Focus Therapeutic Use
- 05 Aug 2015 New trial record
- 15 Jun 2015 Results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.